pyrvinium has been researched along with lithium chloride in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hu, P; Wang, W; Zhang, C; Zhang, S; Zhang, Z | 1 |
Huxlin, KR; Jeon, KI; Phipps, RP; Sime, PJ | 1 |
2 other study(ies) available for pyrvinium and lithium chloride
Article | Year |
---|---|
Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lithium Chloride; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Pyrvinium Compounds; Wnt Signaling Pathway | 2017 |
Antifibrotic Actions of Peroxisome Proliferator-Activated Receptor γ Ligands in Corneal Fibroblasts Are Mediated by β-Catenin-Regulated Pathways.
Topics: Actins; Animals; beta Catenin; Cats; Chromans; Collagen Type I; Cornea; Fibroblasts; Fibronectins; Fibrosis; Glycogen Synthase Kinase 3 beta; Lithium Chloride; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Prostaglandin D2; Pyrvinium Compounds; Receptors, Transforming Growth Factor beta; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone | 2017 |